TRACON Pharmaceuticals, Inc (TCON) Long-Term Debt to Capital Ratio

TRACON Pharmaceuticals (TCON) generates revenue through the development of oncology drugs and payments from counterparties for targeted antibodies. This chart of current market value reflects a debt load that currently stands at 0.00. The company's US base focuses on identifying tumor combat methods through partnerships. Operations are strictly regulated by FDA standards, including biohazardous waste processing rules.

Investors are assessing the financial stability of TRACON Pharmaceuticals (TCON) through the balance of debt and equity. This metric is calculated as the ratio of liabilities with a maturity of over one year to total equity. Analyzing long-term debt relative to equity allows for the monitoring of the business's financing structure. For this developer of targeted antibodies, this is critical when making long-term investments in neoangiogenesis research. Low reliance on loans confirms the company's fundamental reliability.